Shirish M. Gadgeel - Concepedia

Author

Shirish M. Gadgeel

The Barbara Ann Karmanos Cancer Institute ORCID

Also Known As

David P. Carbone, Gadgeel S, Gadgeel, S.M., Halabi, S., S Gadgeel, S. Gadgeel, S. M. Gadgeel, S.M. Gadgeel, SHIRISH GADGEEL, Shirish Gadgeel

843

Publications

41.4K

Citations

H-Index

119

Concepts

All Affiliations

The Barbara Ann Karmanos Cancer Institute Wayne State University University of Michigan Massachusetts General Hospital Dana-Farber Cancer Institute

About

Shirish M. Gadgeel is an author at The Barbara Ann Karmanos Cancer Institute specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	51	151	16.2K
2	Health Sciences	23	38	6.5K
3	Education	2	2	112
4	Engineering	1	1	94
5	Humanities	1	1	11

Shirish M. Gadgeel

262

Publications

39.2K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel, New England Journal of Medicine	2018	6.4K
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp, The Lancet Non-small-cell Lung CancerMedicineMetronomic TherapyClinical TrialsPathology	2016	4.7K
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer Solange Peters, D. Ross Camidge, Alice T. Shaw, New England Journal of Medicine	2017	2.4K
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study Corey J. Langer, Shirish M. Gadgeel, Hossein Borghaei, The Lancet Oncology OncologyMetronomic TherapyPathologyBronchial NeoplasmOpen-label Keynote-021 Study	2016	1.4K
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer Shirish M. Gadgeel, Delvys Rodríguez‐Abreu, Giovanna Speranza, Journal of Clinical Oncology	2020	1.1K
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <i>ALK</i> -Rearranged Lung Cancer Justin F. Gainor, Leila Dardaei, Satoshi Yoda, Cancer Discovery	2016	1.1K
Adagrasib in Non–Small-Cell Lung Cancer Harboring a <i> KRAS <sup>G12C</sup> </i> Mutation Pasi A. Jänne, Gregory J. Riely, Shirish M. Gadgeel, New England Journal of Medicine	2022	886
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study Benjamin Solomon, Benjamin Besse, Todd M. Bauer, The Lancet Oncology OncologyPathologyBronchial NeoplasmGlobal Phase 2Cancer Treatment	2018	772
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study Shirish M. Gadgeel, Leena Gandhi, Gregory J. Riely, The Lancet Oncology Phase 1/2Neuro-oncologyDose-finding PortionBrain MetastasesMedicine	2014	688
Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer Lecia V. Sequist, Jean‐Charles Soria, Jonathan W. Goldman, New England Journal of Medicine	2015	660

Page 1